Mylan gets green light to challenge Neurim melatonin patent

25-01-2022

Muireann Bolger

Mylan gets green light to challenge Neurim melatonin patent

ricochet64 / Shutterstock.com

Mylan has been allowed to challenge Neurim's melatonin patent at trial following a ruling by the High Court of England and Wales that the generic drug maker did not contravene the legal principle of estoppel.


Mylan, Neurim, melatonin, patent, Circadin, issue estoppel, big pharma, generics

LSIPR